Imexpharm Pre-Tax Margin
The Pre-Tax Profit Margin of Imexpharm (IMP.VN) as of Oct 9, 2026 is 18.28 %. In the previous year, Pre-Tax Profit Margin was 18.33 % — a change of -0.27% (lower).
Get this data via API
Financial Data API
Pre-Tax Margin
18.28 %
YoY
-0.27%
Last updated:
The Imexpharm Pre-Tax Margin history
3 Years
10 Years
25 Years
Max
| YEAR | Pre-Tax Margin | YoY |
|---|---|---|
| 18.28 % | -0.27% | |
| 18.33 % | -3.12% | |
| 18.92 % | +6.72% | |
| 17.73 % | -5.99% | |
| 18.86 % | +1.10% | |
| 18.65 % | +29.23% | |
| 14.43 % | -1.58% | |
| 14.67 % | +16.63% | |
| 12.58 % | +0.42% | |
| 12.52 % | +1.75% | |
| 12.31 % | +0.12% | |
| 12.29 % | — |
Imexpharm Stock analysis
Frequently Asked Questions about Imexpharm stock
Pre-Tax Profit Margin of Imexpharm is 18.28 % in 2025.
Pre-Tax Profit Margin of Imexpharm changed from 18.33 % to 18.28 %, representing a -0.27% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Imexpharm since 2006 – with annual values, charts, and detailed analysis.
Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Imexpharm with sector peers and the industry average to assess whether it is attractive.
To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.
Margins — Imexpharm
All Key Metrics — Imexpharm
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth